Isolated from a single, well-characterized induced pluripotent stem cell (iPSC) line, hiEX™ Research iPSC Exosomes offer a consistent and scalable alternative to donor-derived exosomes. While available off-the-shelf in PBS, they can be custom-formulated and even engineered, thanks to the presence of Applied StemCell's patented TARGATT™ large knock-in technology in the source cell line, turning hiEX™ Research iPSC Exosomes into a versatile platform for discovery and translational research. “Exosomes offer exciting possibilities as cell-free tools in regenerative medicine,” said Dr. Ruby Tsai, CEO of Applied StemCell. “Our hiEX™ iPSC Exosomes give researchers a dependable and well-defined starting point for exploring those possibilities.”By combining the scalability of iPSCs with rigorous quality control and the potential for fast gene knock-in into the parent line, hiEX™ Research iPSC Exosomes enable researchers to pursue deeper insights into regenerative mechanisms and lay the groundwork for therapeutic innovations. With expertise in iPSC generation, differentiation, and custom genome engineering, Applied StemCell supports basic and discovery research through GMP and RUO platforms tailored to the needs of biotech, pharma, and academic researchers.